Low expression levels of DUSP6 in NSCLC would affect these pathways by increasing tumorigenicity, cell motility, EMT transition and consequently tumor progression associated with poor prognosis in NSCLC patients. This evidence concerns the gene DUSP6 and non-small cell lung carcinoma.